Abstract
Promoter methylation is an important pathway in transcriptional silencing of known and candidate tumor suppressor genes in Head and Neck Squamous Cell Carcinoma (HNSCC). In order to study the association of tumor suppressor gene promoter methylation in HNSCC with patient clinical characteristics, especially alcohol consumption and tobacco smoking, we examined promoter methylation of the p16INK4a, DAP-kinase, E-Cadherin, and RASSF1A genes using methylation-specific PCR (MSP) in 80 patients. The prevalence of p16INK4a, DAP-kinase, E-Cadherin, and RASSF1A promoter methylation was 26/80 (32.5%), 19/80 (23.8%), 29/80 (36.3%), 6/80 (7.5%) respectively. In 48 cases (60%), at least one of these promoters was methylated. There was a significant association of methylation of any of these genes and ever smoking (P=0.006). p16INK4a gene promoter methylation was associated with a younger age of smoking initiation (P<0.03); E-Cadherin promoter methylation was associated with an increased number of pack years smoked (P<0.03). We also found an association of methylation of any gene and T status (OR=2.7, P<0.05). Tumors with p16INK4a methylation were significantly less likely to show lymph node metastasis (P<0.001). DAP-kinase promoter methylation was significantly associated with lymph node metastasis and this relationship was dependent upon p16INK4a promoter methylation status. Our results suggest that, in HNSCC, promoter methylation of these four genes accumulates with increasing tumor size. This may reflect distinct pathways of somatic inactivation leading to cancer; additional larger studies are needed to further investigate this possibility. Tobacco smoking may play an important role in both the occurrence of promoter methylation as well as delineating the precise pathway that eventually results in a tumorigenic phenotype.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F . 2001 Oncogene 20: 1509–1518
Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . 1998 Adv. Cancer Res. 72: 141–196
Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG . 1998 Proc. Natl. Acad. Sci. USA 95: 11891–11896
Belinsky SA, Nikula KJ, Baylin SB, Issa JP . 1995 Toxicol. Lett. 82: 335–340
Blot WJ, McLaughlin JK, Minn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF . 1988 Cancer Res. 48: 3282–3287
Brandeis M, Ariel M, Cedar H . 1993 Bioessays 15: 709–713
Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD . 2001 J. Natl. Cancer Inst. 93: 691–699
Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenber B, Koch W, Sidransky D . 1996 Cancer Res. 56: 2488–2492
Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP . 2000 Nat. Genet. 25: 315–319
Dammann R, Yang G, Pfeifer GP . 2001a Cancer Res. 61: 3105–3109
Dammann R, Takahashi T, Pfeifer GP . 2001b Oncogene 20: 3563–3567
Eguchi K, Kanai Y, Kobayashi K, Hirohashi S . 1997 Cancer Res. 57: 4913–4915
Esteller M, Corn PG, Baylin SB, Herman JG . 2001 Cancer Res. 61: 3225–3229
Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman G . 1999 Cancer Res. 59: 67–70
Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W . 1991 J. Cell. Biol. 113: 173–185
Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB . 1995 Cancer Res. 55: 5195–5199
Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM . 1997 J. Biol. Chem. 272: 22322–22329
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826
Jost JP . 1993 Proc. Natl. Acad. Sci. USA 90: 4684–4688
Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, Mark EJ, Kelsey KT . 2001a Cancer Res. 61: 3419–3424
Kim DH, Nelson HH, Wiencke JK, Christiani DC, Wain JC, Mark EJ, Kelsey KT . 2001b Oncogene 29: 1765–1770
Kok K, Naylor SL, Buys CH . 1997 Adv. Cancer Res. 71: 27–92
Li E, Bestor TH, Jaenisch R . 1992 Cell 69: 915–926
Lo K-W, Kwong J, Hui A B-Y, Chan S Y-Y, To K-F, Chan A S-C, Chow L S-N, Teo PML, Johnson PJ, Huang DP . 2001 Cancer Res. 61: 3877–3881
Maestro R, Gasparotto D, Vukosavljevic T, Barzan L, Sulfaro S, Boiocchi M . 1993 Cancer Res. 53: 5775–5779
Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER . 2001 Cancer Res. 61: 7277–7281
Nagai MA . 1999 Braz. J. Med. Biol. Res. 32: 897–904
Navarro P, Gomez M, Pizarro A, Gamallo C, Quintanilla M, Cano A . 1991 J. Cell Biol. 115: 517–533
Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimchi A . 2001 Nat. Cell Biol. 3: 1–7
Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D . 1996 Cancer Res. 56: 3630–3633
Riese U, Dahse R, Fiedler W, Theuer C, Koscielny S, Ernst G, Beleites E, Claussen U, von Eggeling F . 1999 Int. J. Mol. Med. 4: 61–65
Rosas SLB, Koch W, Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D . 2001 Cancer Res. 61: 939–942
Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D . 2000 Cancer Res. 60: 892–895
Saracci R . 1987 Epidemiol. Rev. 9: 175–193
Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W . 1991 Cancer Res. 51: 6328–6337
Serrano M, Hannon GJ, Beach D . 1993 Nature 366: 704–707
Spitz MR, Trizna Z . 1999 Head and Neck Cancer. Harrison LB, Sessions RB and Hong WK. (eds) Philadelphia: Lippincott-Raven pp 11–22
Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F . 1991 Cell 66: 107–119
Yarbrough WG, Shores C, Witsell DL, Weissler MC, Fidler ME, Gilmer TM . 1994 Laryngoscope 104: 1337–1347
Yoon JH, Dammann R, Pfeifer GP . 2001 Int. J. Cancer 94: 212–217
Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD . 2001 Cancer Res. 61: 249–255
Acknowledgements
Supported by: CA78609, ES08357, ES00002 and 1P01-DE12467-05.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hasegawa, M., Nelson, H., Peters, E. et al. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 21, 4231–4236 (2002). https://doi.org/10.1038/sj.onc.1205528
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205528
Keywords
This article is cited by
-
DNA methylation in the genesis, progress and prognosis of head and neck cancer
Holistic Integrative Oncology (2023)
-
Portrait of DNA methylated genes predictive of poor prognosis in head and neck cancer and the implication for targeted therapy
Scientific Reports (2021)
-
Metabolic Phase I (CYPs) and Phase II (GSTs) Gene Polymorphisms and Their Interaction with Environmental Factors in Nasopharyngeal Cancer from the Ethnic Population of Northeast India
Pathology & Oncology Research (2019)
-
The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort
British Journal of Cancer (2018)
-
The regulatory mechanisms of NG2/CSPG4 expression
Cellular & Molecular Biology Letters (2017)